Heidelberg Pharma AG
XMUN:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Heidelberg Pharma AG
XMUN:HPHA
|
DE |
|
China Coal Energy Co Ltd
OTC:CCOZF
|
CN |
|
F
|
First Advantage Corp
NASDAQ:FA
|
US |
|
Continental AG
OTC:CTTAF
|
DE |
|
Gear4music (Holdings) PLC
F:G4A
|
UK |
|
O
|
Omnicell Inc
F:OC9
|
US |
|
E
|
Eni SpA
F:ENI
|
IT |
|
M
|
MacroAsia Corp
XPHS:MAC
|
PH |
|
Clemondo Group AB (publ)
F:N17
|
SE |
|
O
|
Oddity Tech Ltd
NASDAQ:ODD
|
IL |
|
Elecnor SA
OTC:ELNRF
|
ES |
|
Elixirr International PLC
F:54K
|
UK |
|
Canal+ SA
F:YA3
|
FR |
|
NetEase Inc
LSE:0K6G
|
CN |
|
B
|
Basf Se
BMV:BASN
|
DE |
|
M
|
Mediobanca Banca di Credito Finanziario SpA
SWB:ME9
|
IT |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
US |
|
E
|
Extra Space Storage Inc
F:FG8
|
US |
|
R
|
Relx PLC
XMUN:RDEB
|
UK |
|
Basf Se
MIL:1BAS
|
DE |
|
A
|
Allianz SE
F:ALV
|
DE |
|
G
|
Glencore PLC
JSE:GLN
|
CH |
|
B
|
Bradespar SA
XBER:FXMA
|
BR |
|
S
|
Smurfit Kappa Group PLC
F:SK3
|
IE |
Heidelberg Pharma AG
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin. The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer. For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin.
The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer.
For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
